ArticleLung2013
Inflammatory biomarkers in sputum predict COPD exacerbations.
Article in Lung, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Oxidative Stress Biomarkers in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review.Antioxidants (Basel, Switzerland) · 2021Review
- The neutrophil-mobilizing cytokine interleukin-26 in the airways of long-term tobacco smokers.Clinical science (London, England : 1979) · 2018Article
- Metabolomic similarities between bronchoalveolar lavage fluid and plasma in humans and mice.Scientific reports · 2017Observational
- Inflammation and chronic colonization ofInternational journal of chronic obstructive pulmonary disease · 2017Article
- Structurally Related Monoterpenes p-Cymene, Carvacrol and Thymol Isolated from Essential Oil from Leaves of Lippia sidoides Cham. (Verbenaceae) Protect Mice against Elastase-Induced Emphysema.Molecules (Basel, Switzerland) · 2016Article
- Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients.International journal of chronic obstructive pulmonary disease · 2016Observational
- Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Inflammation · 2015Article
- Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood.Respiratory research · 2015Observational
- Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation.International journal of chronic obstructive pulmonary disease · 2015Article
- Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.International journal of chronic obstructive pulmonary disease · 2015Article
- Biomarkers of progression of chronic obstructive pulmonary disease (COPD).Journal of thoracic disease · 2014Review
- Oxidative stress and free radicals in COPD--implications and relevance for treatment.International journal of chronic obstructive pulmonary disease · 2014Review
- Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study.PloS one · 2014Article
- Cholinergic mechanisms in an organic dust model simulating an acute exacerbation in patients with COPD.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionExacerbations in chronic obstructive pulmonary disease (COPD) reduce quality of life and are associated with a more rapid deterioration of the disease. It is desirable to predict an oncoming exacerbation before it occurs. The aim of the present study was to identify biomarkers that may predict a forthcoming exacerbation. MATERIALS AND
methodsForty-three patients with COPD in their stable state were included and followed up monthly until exacerbation, or for a maximum of 6 months. The patients come for an extra visit (prior to a scheduled visit) when exacerbated. The patients completed the questionnaires CCQ and MRC. Exhaled breath condensate (EBC) was collected followed by spirometry, impulse oscillometry, and sputum induction.
resultsTwenty-five patients had an exacerbation within the 6-month period. Leukotriene B4 in sputum was the only biomarker that was increased at the visit prior to exacerbation compared to at the stable phase (p = 0.05). There also was a tendency for a similar but not significant increase in the sputum levels of 8-isoprostane, myeloperoxidase activity, and interleukin-8, as well as additional increases during exacerbation. Sputum purulence was not increased until exacerbation (p = 0.02). In contrast, none of the inflammatory biomarkers in EBC, the quality-of-life questionnaire score, CRP, spirometric parameters, or impulse oscillometry parameters were increased at the visit prior to exacerbation compared to the values at the stable phase.
conclusionSputum biomarkers, especially leukotriene B4, could be used as predictors of a forthcoming exacerbation and worsening of COPD. This would be of great value for the patient, who may be a subject for early treatment and thereby avoid a progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.